Selected article for: "antigen specificity and high specificity"

Author: Saeed, Abdullah F. U. H.; Wang, Rongzhi; Ling, Sumei; Wang, Shihua
Title: Antibody Engineering for Pursuing a Healthier Future
  • Document date: 2017_3_28
  • ID: 0fegsm1v_56
    Snippet: ScFv has high affinity, highly solubility, multi-domains, and high binding specificity with their target antigen and they are used for antibody engineering, biotechnology, cancer research, and biomedical applications. ScFv have been engineered to improve the effector functions of full-length antibodies, carrying toxins to kill cells, or cytokines to activate the immune system. Furthermore, bispecific antibodies have been constructed to target mul.....
    Document: ScFv has high affinity, highly solubility, multi-domains, and high binding specificity with their target antigen and they are used for antibody engineering, biotechnology, cancer research, and biomedical applications. ScFv have been engineered to improve the effector functions of full-length antibodies, carrying toxins to kill cells, or cytokines to activate the immune system. Furthermore, bispecific antibodies have been constructed to target multiple receptors . Recombinant antibody engineering and recombinant DNA technology has facilitated successful expression and cloning of widespread antibody fragments in bacteria (E. coli), as well as mammalian (Chinese hamster ovary (CHO), or myeloma cell lines e.g., Sp2/0), yeast (Pichia pastoris), plant (Arabidopsis), and insect cells (Drosophila melanogaster) (Frenzel et al., 2013) . These smaller fragments have several advantages over fulllength antibodies such as tumor and tissue penetration, blood clearance, short retention times, and reduced immunogenicity. Likewise, they have better fusion in bacteria, and display on a filamentous phage. These fragments permit the production of homogenous proteins for diagnostic and therapeutic purposes as well as structural studies (Frenzel et al., 2013; Wu et al., 2016) .

    Search related documents:
    Co phrase search for related documents
    • antibody engineering and bispecific antibody: 1, 2
    • antibody fragment and binding specificity: 1
    • antibody fragment and cancer research: 1
    • antibody fragment and cell kill: 1
    • antibody fragment and cell line: 1, 2, 3
    • antigen target and binding specificity: 1, 2
    • antigen target and bispecific antibody: 1, 2
    • antigen target and blood clearance: 1
    • antigen target and cell line: 1, 2, 3, 4
    • binding specificity and blood clearance: 1, 2
    • binding specificity and cancer research: 1
    • binding specificity and cell line: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • binding specificity and chinese hamster: 1
    • binding specificity and chinese hamster CHO ovary: 1
    • binding specificity and CHO ovary: 1
    • bispecific antibody and blood clearance: 1
    • bispecific antibody and cell line: 1
    • blood clearance and cancer research: 1
    • cancer research and CHO ovary: 1